Orphan drug development

Area of Science:

• Biotechnology and Genetic Medicine
• Pharmacology and Drug Development
• Rare Disease Research

Background:

• Lysosomal storage disorders (LSDs) are a group of rare genetic diseases.
• The Orphan Drug Act (ODA) of 1983 and the Bayh-Dole Act of 1980 have been instrumental in fostering therapeutic development for LSDs.
• Early commercial treatments for Gaucher disease emerged in 1991, followed by therapies for other LSDs like Fabry disease.

Purpose of the Study:

• To review the historical development and current landscape of therapies for lysosomal storage disorders.
• To highlight the role of public-private partnerships and legislation in driving innovation for rare diseases.
• To identify ongoing challenges and future directions in LSD treatment.

Main Methods:

• Review of historical legislative acts (Orphan Drug Act, Bayh-Dole Act).
• Analysis of the development of commercial enzyme therapies for LSDs.
• Examination of ongoing data collection through patient registries and observational studies.
• Discussion of emerging therapeutic modalities and persistent challenges.

Main Results:

• Several enzyme therapies are now available for various LSDs, significantly altering disease progression.
• Collaborations between government institutions (NIH) and biotechnology companies (Genzyme) have been crucial for therapeutic breakthroughs.
• Ongoing research is exploring novel treatments, including small molecule drugs and pharmacologic chaperones.
• Registry data are essential for evaluating long-term safety and efficacy of existing therapies.

Conclusions:

• Therapeutic options for LSDs have expanded considerably, improving patient outcomes.
• Despite progress, challenges remain, particularly concerning bone and brain manifestations of LSDs.
• High therapy costs and equitable access to treatment are critical issues requiring further attention and innovative solutions.